Bacteria and their toxins tamed for immunotherapy

Current Pharmaceutical Biotechnology
Irena AdkinsLenka Sadilkova

Abstract

Bacterial toxins share the ability to enter host cells to target various intracellular proteins and to modulate host immune responses. Over the last 20 years, toxins and their mutated variants, as well as live attenuated bacteria, have been exploited for vaccination and immunotherapy of various infectious, malignant and autoimmune diseases. The ability of Bordetella pertussis adenylate cyclase toxin to translocate its adenylate cyclase domain across the host cell membrane, as well as the pathways of intracellular trafficking of Bacillus anthracis lethal and edema toxins, Shigella dysenteriae shiga toxin or Escherichia coli shiga-like toxin, have been repeatedly exploited for the delivery of antigenic epitopes into host cells and for stimulation of antigen-specific T cell responses. Similarly, E. coli α-hemolysin, or effector proteins of Yersinia and Salmonella secreted by the type III secretion systems, were used to facilitate the delivery of fused heterologous proteins or peptides for antigenic presentation. Vibrio cholerae cholera toxin, E. coli heat-labile enterotoxin, B. pertussis pertussis toxin or the Cry1A protein of Bacillus thuringiensis have shown a great potential to act as adjuvants and to stimulate mucosal as well ...Continue Reading

Citations

Oct 13, 2012·Chemical Reviews·Ekaterina M Nestorovich, Sergey M Bezrukov
Nov 13, 2012·PLoS Pathogens·Christine Rueckert, Carlos A Guzmán
Apr 1, 2014·BioMed Research International·Leonardo A CalderonAndreimar M Soares
Jan 21, 2016·Expert Review of Respiratory Medicine·Jordi Rello, Antonio Perez
Aug 26, 2014·Toxins·Philip A Gurnev, Ekaterina M Nestorovich
Oct 7, 2015·Immunology and Cell Biology·Martina SvedovaPeter Sebo
Nov 28, 2012·Biochemical Society Transactions·Mireille VankemmelbekeChristopher N Penfold
Jan 1, 2014·FEMS Microbiology Reviews·Gordon Y C CheungMichael Otto
Apr 28, 2016·Emerging Microbes & Infections·Biao HeShibo Jiang
Feb 24, 2018·Frontiers in Microbiology·M Gabriela KramerRobert M Hoffman
Jun 22, 2019·FEMS Microbiology Letters·Sergio Rius-RocabertEstanislao Nistal-Villan
Nov 24, 2020·Chemical Society Reviews·Guo-Feng LuoXian-Zheng Zhang
Apr 4, 2013·Molecular Pharmaceutics·Gaëlle VacherGerrit Borchard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.